Consensus recommendations for the diagnosis and clinical
management of Rosai-Dorfman-Destombes disease

J 2018

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

ABLA, Oussama, Eric JACOBSEN, Jennifer PICARSIC, Zdenka KŘENOVÁ, Ronald JAFFE et. al.

Basic information

Original name

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

Authors

ABLA, Oussama (124 Canada, guarantor), Eric JACOBSEN (840 United States of America), Jennifer PICARSIC (840 United States of America), Zdenka KŘENOVÁ (203 Czech Republic, belonging to the institution), Ronald JAFFE (840 United States of America), Jean-Francois EMILE (250 France), Benjamin H. DURHAM (840 United States of America), Jorge BRAIER (32 Argentina), Frederic CHARLOTTE (250 France), Jean DONADIEU (250 France), Fleur COHEN-AUBART (250 France), Carlos RODRIGUEZ-GALINDO (840 United States of America), Carl ALLEN (840 United States of America), James A. WHITLOCK (124 Canada), Sheila WEITZMAN (124 Canada), Kenneth L. MCCLAIN (840 United States of America), Julien HAROCHE (250 France) and Eli L. DIAMOND (840 United States of America)

Edition

Blood, Washington, American Society of Hematology, 2018, 0006-4971

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 16.601

RIV identification code

RIV/00216224:14110/18:00104163

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1182/blood-2018-03-839753

UT WoS

000439123700004

Keywords in English

Rosai-Dorfman-Destombes disease

Abstract

V originále

Rosai-Dorfman-Destombes disease (RDD) is a rare non-Langerhans cell histiocytosis characterized by accumulation of activated histiocytes within affected tissues. RDD, which now belongs to the R group of the 2016 revised histiocytosis classification, is a widely heterogeneous entity with a range of clinical phenotypes occurring in isolation or in association with autoimmune or malignant diseases. Recent studies have found NRAS, KRAS, MAP2K1, and ARAF mutations in lesional tissues, raising the possibility of a clonal origin in some forms of RDD. More than 1000 reports have been published in the English literature; however, there is a lack of consensus regarding approach for the clinical management of RDD. Although in most cases RDD can be observed or treated with local therapies, some patients with refractory or multifocal disease experience morbidity and mortality. Here we provide the first consensus multidisciplinary recommendations for the diagnosis and management of RDD. These recommendations were discussed at the 32nd Histiocyte Society Meeting by an international group of academic clinicians and pathologists with expertise in RDD. We include guidelines for clinical, laboratory, pathologic, and radiographic evaluation of patients with RDD together with treatment recommendations based on clinical experience and review of the literature.

Citovat

ABLA, Oussama, Eric JACOBSEN, Jennifer PICARSIC, Zdenka KŘENOVÁ, Ronald JAFFE, Jean-Francois EMILE, Benjamin H. DURHAM, Jorge BRAIER, Frederic CHARLOTTE, Jean DONADIEU, Fleur COHEN-AUBART, Carlos RODRIGUEZ-GALINDO, Carl ALLEN, James A. WHITLOCK, Sheila WEITZMAN, Kenneth L. MCCLAIN, Julien HAROCHE and Eli L. DIAMOND. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. Washington: American Society of Hematology, 2018, vol. 131, No 26, p. 2877-2890. ISSN 0006-4971. Available from: https://dx.doi.org/10.1182/blood-2018-03-839753.

@article{1454376,
   author = {Abla, Oussama and Jacobsen, Eric and Picarsic, Jennifer and Křenová, Zdenka and Jaffe, Ronald and Emile, JeanandFrancois and Durham, Benjamin H. and Braier, Jorge and Charlotte, Frederic and Donadieu, Jean and CohenandAubart, Fleur and RodriguezandGalindo, Carlos and Allen, Carl and Whitlock, James A. and Weitzman, Sheila and McClain, Kenneth L. and Haroche, Julien and Diamond, Eli L.},
   article_location = {Washington},
   article_number = {26},
   doi = {http://dx.doi.org/10.1182/blood-2018-03-839753},
   keywords = {Rosai-Dorfman-Destombes disease},
   language = {eng},
   issn = {0006-4971},
   journal = {Blood},
   title = {Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease},
   volume = {131},
   year = {2018}
}

TY  - JOUR
ID  - 1454376
AU  - Abla, Oussama - Jacobsen, Eric - Picarsic, Jennifer - Křenová, Zdenka - Jaffe, Ronald - Emile, Jean-Francois - Durham, Benjamin H. - Braier, Jorge - Charlotte, Frederic - Donadieu, Jean - Cohen-Aubart, Fleur - Rodriguez-Galindo, Carlos - Allen, Carl - Whitlock, James A. - Weitzman, Sheila - McClain, Kenneth L. - Haroche, Julien - Diamond, Eli L.
PY  - 2018
TI  - Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease
JF  - Blood
VL  - 131
IS  - 26
SP  - 2877-2890
EP  - 2877-2890
PB  - American Society of Hematology
SN  - 00064971
KW  - Rosai-Dorfman-Destombes disease
N2  - Rosai-Dorfman-Destombes disease (RDD) is a rare non-Langerhans cell histiocytosis characterized by accumulation of activated histiocytes within affected tissues. RDD, which now belongs to the R group of the 2016 revised histiocytosis classification, is a widely heterogeneous entity with a range of clinical phenotypes occurring in isolation or in association with autoimmune or malignant diseases. Recent studies have found NRAS, KRAS, MAP2K1, and ARAF mutations in lesional tissues, raising the possibility of a clonal origin in some forms of RDD. More than 1000 reports have been published in the English literature; however, there is a lack of consensus regarding approach for the clinical management of RDD. Although in most cases RDD can be observed or treated with local therapies, some patients with refractory or multifocal disease experience morbidity and mortality. Here we provide the first consensus multidisciplinary recommendations for the diagnosis and management of RDD. These recommendations were discussed at the 32nd Histiocyte Society Meeting by an international group of academic clinicians and pathologists with expertise in RDD. We include guidelines for clinical, laboratory, pathologic, and radiographic evaluation of patients with RDD together with treatment recommendations based on clinical experience and review of the literature.
ER  -

ABLA, Oussama, Eric JACOBSEN, Jennifer PICARSIC, Zdenka KŘENOVÁ, Ronald JAFFE, Jean-Francois EMILE, Benjamin H. DURHAM, Jorge BRAIER, Frederic CHARLOTTE, Jean DONADIEU, Fleur COHEN-AUBART, Carlos RODRIGUEZ-GALINDO, Carl ALLEN, James A. WHITLOCK, Sheila WEITZMAN, Kenneth L. MCCLAIN, Julien HAROCHE and Eli L. DIAMOND. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. \textit{Blood}. Washington: American Society of Hematology, 2018, vol.~131, No~26, p.~2877-2890. ISSN~0006-4971. Available from: https://dx.doi.org/10.1182/blood-2018-03-839753.

Detailed Information on Publication Record